SI0883404T1 - Kombinirana terapija za osteoporozo - Google Patents

Kombinirana terapija za osteoporozo

Info

Publication number
SI0883404T1
SI0883404T1 SI9630762T SI9630762T SI0883404T1 SI 0883404 T1 SI0883404 T1 SI 0883404T1 SI 9630762 T SI9630762 T SI 9630762T SI 9630762 T SI9630762 T SI 9630762T SI 0883404 T1 SI0883404 T1 SI 0883404T1
Authority
SI
Slovenia
Prior art keywords
osteoporosis
combination therapy
therapy
combination
Prior art date
Application number
SI9630762T
Other languages
English (en)
Inventor
Hua Zhu Ke
David D Thompson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SI0883404T1 publication Critical patent/SI0883404T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SI9630762T 1996-02-28 1996-12-23 Kombinirana terapija za osteoporozo SI0883404T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1241296P 1996-02-28 1996-02-28
PCT/IB1996/001462 WO1997031640A1 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis
EP96941153A EP0883404B1 (en) 1996-02-28 1996-12-23 Combination therapy for osteoporosis

Publications (1)

Publication Number Publication Date
SI0883404T1 true SI0883404T1 (sl) 2008-10-31

Family

ID=21754846

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630762T SI0883404T1 (sl) 1996-02-28 1996-12-23 Kombinirana terapija za osteoporozo

Country Status (45)

Country Link
US (2) US6323232B1 (sl)
EP (3) EP1932543A3 (sl)
JP (2) JPH11504352A (sl)
KR (1) KR19990087337A (sl)
CN (5) CN1515317A (sl)
AP (3) AP974A (sl)
AR (2) AR005987A1 (sl)
AT (1) ATE405273T1 (sl)
AU (1) AU703285B2 (sl)
BG (1) BG64582B1 (sl)
BR (1) BR9612533A (sl)
CA (1) CA2247420C (sl)
CL (1) CL2004000119A1 (sl)
CO (1) CO4761063A1 (sl)
CZ (1) CZ297452B6 (sl)
DE (1) DE69637651D1 (sl)
DK (1) DK0883404T3 (sl)
DZ (1) DZ2186A1 (sl)
ES (1) ES2312169T3 (sl)
GT (2) GT199700009A (sl)
HK (1) HK1018210A1 (sl)
HN (1) HN1996000101A (sl)
HR (1) HRP970118A2 (sl)
HU (1) HUP9904123A3 (sl)
ID (1) ID19886A (sl)
IL (3) IL125493A0 (sl)
IS (1) IS4812A (sl)
MA (1) MA26420A1 (sl)
NO (2) NO323648B1 (sl)
NZ (1) NZ323456A (sl)
OA (1) OA10837A (sl)
PE (2) PE58998A1 (sl)
PL (2) PL187219B1 (sl)
PT (1) PT883404E (sl)
RU (1) RU2190395C2 (sl)
SI (1) SI0883404T1 (sl)
SK (1) SK118398A3 (sl)
TN (1) TNSN97040A1 (sl)
TR (1) TR199801679T2 (sl)
TW (1) TW464496B (sl)
UA (1) UA69372C2 (sl)
UY (1) UY24472A1 (sl)
WO (1) WO1997031640A1 (sl)
YU (1) YU7797A (sl)
ZA (1) ZA971719B (sl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AR008155A1 (es) * 1996-09-06 1999-12-09 Smithkline Beecham Corp Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres.
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
SE9702401D0 (sv) * 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
AU7349298A (en) * 1997-06-23 1999-01-04 Pfizer Inc. Prostaglandin agonists
CN1269720A (zh) * 1997-09-09 2000-10-11 普罗克特和甘保尔公司 增加骨容量的方法
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP0950417A3 (en) * 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
CN1303379A (zh) * 1998-06-03 2001-07-11 辉瑞产品公司 作为氧化氮合酶抑制剂的含稠环取代基的2－氨基吡啶
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea
AU3342099A (en) * 1998-06-16 2000-01-05 Pfizer Products Inc. Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
DK0966968T3 (da) 1998-06-16 2004-08-30 Pfizer Prod Inc Terapeutiske kombinationer, der omfatter en selektiv östrogenreceptormodulator og prostaglandin E2
PA8475901A1 (es) * 1998-06-16 2000-05-24 Pfizer Prod Inc Terapia de combinacion para la fragilidad musculoesqueletica
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
HUP0104192A3 (en) 1998-11-03 2003-12-29 Pfizer Prod Inc Novel macrolide antibiotics
NZ513827A (en) * 1999-03-05 2001-09-28 Procter & Gamble Methods of increasing bone volume using non-naturally-occurring FP selective agonists and antiresorptive compounds
GB9913649D0 (en) * 1999-06-11 1999-08-11 Karobio Ab Estrogen receptor
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CO5251465A1 (es) 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
KR100795870B1 (ko) * 2000-06-01 2008-01-21 왓슨 파머수티컬즈, 인코포레이티드 라소폭시펜의 경피적 송달
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis
IL145876A0 (en) * 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
EP1210951B1 (en) * 2000-11-30 2005-02-02 Pfizer Products Inc. Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone
PL367094A1 (en) * 2001-07-31 2005-02-21 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
MY143244A (en) 2002-11-26 2011-04-15 Smithkline Beecham Corp Calcilytic compounds
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2013049507A1 (en) 2011-09-30 2013-04-04 Perio Sciences, Llc Antioxidant compositions for treatment of inflammation or oxidative damage
CN103142644B (zh) * 2013-03-21 2014-07-23 青岛正大海尔制药有限公司 骨化三醇和氟化钠的混悬颗粒及其制备方法
KR102623130B1 (ko) 2016-10-11 2024-01-10 듀크 유니버시티 Er+ 유방암의 라소폭시펜 치료
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
CN112384634B (zh) * 2018-04-24 2024-04-16 深圳华大生命科学研究院 骨质疏松生物标志物及其用途
CN110412289B (zh) * 2019-07-25 2022-08-02 北京美迪阿姆科技发展有限公司 抑制性t细胞及筛选方法和抑制自身免疫反应中的应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
BE637389A (sl) 1962-09-13
US3522319A (en) 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US3927197A (en) 1974-04-19 1975-12-16 Pfizer Tertiary alcohol stabilized E-series prostaglandins
US3932389A (en) 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US3982016A (en) 1975-08-06 1976-09-21 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4000309A (en) 1975-08-06 1976-12-28 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4018892A (en) 1975-08-06 1977-04-19 Pfizer Inc. Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4132847A (en) 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4097601A (en) 1977-08-26 1978-06-27 Pfizer Inc. Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins
US4171331A (en) 1978-06-05 1979-10-16 Miles Laboratories, Inc. 1 And 2-substituted analogues of certain prostaglandins
US4219483A (en) 1978-09-11 1980-08-26 Pfizer Inc. 4-Pyrone prostaglandin antagonists
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4621100A (en) 1981-09-25 1986-11-04 The Upjohn Company Treatment of osteoporosis with prostaglandins
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
US4904478A (en) 1983-08-11 1990-02-27 Mission Pharmacal Company Slow-release sodium fluoride tablet and method for treatment of osteoporosis
DE3587956T2 (de) 1984-04-30 1995-05-24 Procter & Gamble Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB2196003A (en) 1986-09-11 1988-04-20 Nat Res Dev Iodo-and bromo-tamoxifen derivatives
US5216183A (en) 1988-04-19 1993-06-01 Teijin Limited Cyclopentanone/cyclopentenone derivative
JP2557779B2 (ja) 1990-11-26 1996-11-27 アール． レッカー，ロバート ２成分型骨粗鬆症用薬剤
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
US5180720A (en) 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
US5409911A (en) 1992-09-11 1995-04-25 Merck & Co., Inc. Prostaglandin analog for treating osteoporosis
RU2168512C2 (ru) 1992-12-11 2001-06-10 Мерк Энд Ко., Инк. Спиропиперидины, способы их получения (варианты)
US5536716A (en) 1992-12-11 1996-07-16 Merck & Co., Inc. Spiro piperidines and homologs which promote release of growth hormone
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
TW303299B (sl) 1993-07-22 1997-04-21 Lilly Co Eli
EP0813414A4 (en) * 1993-10-19 1999-07-21 Merck & Co Inc COMBINATION OF BISPHOSPHONATES AND THE GROWTH HORMONE SECRETION PROMOTING SUBSTANCES
SK56296A3 (en) 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
US5492916A (en) 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
EP0730578A4 (en) 1993-11-24 1997-10-08 Merck & Co Inc COMPOUNDS CONTAINING AN INDOLYL GROUP AND THEIR USE FOR PROMOTING THE RELEASE OF GROWTH HORMONES
US5441966A (en) 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
WO1995034311A1 (en) 1994-06-13 1995-12-21 Merck & Co., Inc. Piperazine compounds promote release of growth hormone
CA2199251A1 (en) * 1994-09-09 1996-03-14 Ann Dunbar Geddes Phosphonates and parathyroid hormone for osteoporosis
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5767124A (en) 1995-10-27 1998-06-16 Merck & Co., Inc. Polymorphic forms of a growth hormone secretagogue
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
IL120270A0 (en) 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US6100301A (en) 1996-02-28 2000-08-08 Pfizer Inc Combination therapy to treat osteoporosis-polyphosphonates and estrogen agonists
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
AU730856C (en) 1996-05-07 2001-11-15 Pfizer Inc. Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol- 3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)- indol-2-one(=ziprasidone),it's preparation and it's use as dopamine D2 antagonist
PL330239A1 (en) 1996-05-31 1999-05-10 Novo Nordisk As Growt hormone constituent and bone reserption preventing factor in cyclic (coherent) treatment
GB2324726A (en) 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
UA53716C2 (uk) * 1997-06-25 2003-02-17 Пфайзер Продактс Інк. Тартратна сіль заміщеного дипептиду, спосіб її одержання, проміжні сполуки та спосіб їх одержання, фармацевтична композиція (варіанти), спосіб підвищення рівнів ендогенного гормону росту та спосіб лікування або профілактики захворювань (варіанти)
BR9803596A (pt) 1997-09-23 2000-04-25 Pfizer Prod Inc Derivados do resorcinol.
PA8471201A1 (es) * 1998-06-16 2000-09-29 Pfizer Prod Inc Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea

Also Published As

Publication number Publication date
HK1018210A1 (en) 1999-12-17
NO20063853L (no) 1998-08-27
CZ297452B6 (cs) 2006-12-13
ATE405273T1 (de) 2008-09-15
PT883404E (pt) 2008-11-14
PL187219B1 (pl) 2004-06-30
HRP970118A2 (en) 1998-04-30
IL154379A0 (en) 2003-09-17
CN1515317A (zh) 2004-07-28
BG102726A (en) 1999-04-30
EP1236475A2 (en) 2002-09-04
EP1932543A3 (en) 2012-01-04
CL2004000119A1 (es) 2005-02-11
PE20011302A1 (es) 2001-12-25
EP0883404A1 (en) 1998-12-16
AR005987A1 (es) 1999-07-21
CO4761063A1 (es) 1999-04-27
AP9700934A0 (en) 1997-04-30
US20010009920A1 (en) 2001-07-26
KR19990087337A (ko) 1999-12-27
RU2190395C2 (ru) 2002-10-10
CN1515258A (zh) 2004-07-28
AP2000001962A0 (en) 2000-12-31
BG64582B1 (bg) 2005-08-31
GT199700009A (es) 1998-07-10
CN1209064A (zh) 1999-02-24
EP0883404B1 (en) 2008-08-20
MA26420A1 (fr) 2004-12-20
ID19886A (id) 1998-08-13
AU1039897A (en) 1997-09-16
CZ271898A3 (cs) 1999-06-16
IL154380A0 (en) 2003-09-17
ZA971719B (en) 1998-08-27
CN1515316A (zh) 2004-07-28
EP1932543A2 (en) 2008-06-18
UA69372C2 (en) 2004-09-15
AR060853A2 (es) 2008-07-16
CA2247420A1 (en) 1997-09-04
US7255984B2 (en) 2007-08-14
NZ323456A (en) 2001-03-30
CN1242813C (zh) 2006-02-22
WO1997031640A1 (en) 1997-09-04
SK118398A3 (en) 2000-07-11
IL125493A0 (en) 1999-03-12
TW464496B (en) 2001-11-21
ES2312169T3 (es) 2009-02-16
JP2002308771A (ja) 2002-10-23
AU703285B2 (en) 1999-03-25
GT199700009AA (es) 1999-01-23
AP1179A (en) 2003-06-30
DK0883404T3 (da) 2008-10-20
PL328831A1 (en) 1999-02-15
PE58998A1 (es) 1998-10-16
YU7797A (sh) 2000-10-30
OA10837A (en) 2001-08-13
IS4812A (is) 1998-07-28
BR9612533A (pt) 1999-07-20
AP975A (en) 2001-06-12
CA2247420C (en) 2011-02-15
NO323648B1 (no) 2007-06-18
HUP9904123A3 (en) 2001-01-29
NO983936D0 (no) 1998-08-27
US6323232B1 (en) 2001-11-27
HN1996000101A (es) 1997-06-26
CN1515254A (zh) 2004-07-28
AP974A (en) 2001-06-12
AP2002002661A0 (en) 2002-12-31
HUP9904123A2 (hu) 2000-05-28
DZ2186A1 (fr) 2002-12-02
NO983936L (no) 1998-08-27
TR199801679T2 (xx) 2001-06-21
PL187962B1 (pl) 2004-11-30
TNSN97040A1 (fr) 2005-03-15
UY24472A1 (es) 2000-09-29
JPH11504352A (ja) 1999-04-20
EP1236475A3 (en) 2003-11-05
DE69637651D1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
IL154380A0 (en) Combination therapy for osteoporosis
EG24678A (en) Combination therapy
IL112455A0 (en) Combination treatment for osteoporosis
IL127306A0 (en) Combination therapy
ZA973209B (en) Therapeutic compounds.
EP0944635A4 (en) THERAPEUTIC DIPHOSPHONATE COMPOUNDS
GB9700939D0 (en) Therapy
ZA971711B (en) Combination therapy to treat osteoporosis
GB9600143D0 (en) Therapeutic compounds
GB9414909D0 (en) Osteoporosis apparatus
GB9716344D0 (en) Therapeutic compounds
PL320564A1 (en) Therapeutic set for treating osteoporosis
ZA9711533B (en) Therapeutic compounds
GB2309083B (en) Osteoporosis apparatus
ZA977005B (en) Therapeutic uses
GB2321121B (en) Microprocessor
GB9708698D0 (en) Materials for therapy
GB9615350D0 (en) Hormone replacement therapy
GB9605525D0 (en) Therapy
GB9605466D0 (en) Therapy
GB9608547D0 (en) Therapeutic compounds
GB9613017D0 (en) Therapeutic compounds
GB9608372D0 (en) Therapeutic compounds
GB9700821D0 (en) Retarder unit
GB9704885D0 (en) Therapy